

04/07/98

PTO/SB/05 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No.	801.87.US01	Total Pages	52
		First Named Inventor or Application Identifier			
		Thomas H. TURPEN			
		Express Mail Label No.	EM555262225US		
APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231			
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Form PTO-1082) <i>(Submit an original and a duplicate for fee processing)</i>		6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i>			
2. <input checked="" type="checkbox"/> Specification [Total Pages <input type="text" value="42"/>] <i>(preferred arrangement set forth below)</i> <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R&D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claims- Abstract of the Disclosure		7. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Copyb. <input type="checkbox"/> Paper Copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies			
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <input type="text" value="8"/>]		ACCOMPANYING APPLICATION PARTS			
4. <input type="checkbox"/> Oath or Declaration [Total Pages <input type="text" value="2"/>] <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <i>[Note Box 5 below]</i><ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))			
		9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i>			
		10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i>			
		11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations			
		12. <input checked="" type="checkbox"/> Preliminary Amendment			
		13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Two) <i>(should be specifically itemized)</i>			
		14. <input checked="" type="checkbox"/> Small Entity Statement(s) <input checked="" type="checkbox"/> Statement filed in prior application, Status still proper and desired			
		15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>			
		16. <input type="checkbox"/> Other:			
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 08/324,003					
18. CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number or Bar Code Label or <input checked="" type="checkbox"/> Correspondence address below <i>(Insert Customer No. or Attach bar code label here)</i>					
NAME		Albert P. Halluin (Reg. No. 25, 227) HOWREY & SIMON			
ADDRESS		Box No. 34 1299 Pennsylvania Avenue, N.W.			
CITY	Washington	STATE	DC	ZIP CODE	20004-2402
COUNTRY	US	TELEPHONE	202-783-0800	FAX	202-383-7195

HOWREY & SIMON
Box No. 34
1299 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2402
(650) 463-8100

Attorney Docket No. **801.87.US01****Box Patent Application**

ASSISTANT COMMISSIONER FOR PATENTS
 Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of **Thomas H. Turpen; Stephen J. Reinl; and Lawrence K. Grill** for **PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSIONS**

Also, enclosed are:

1. 8 sheets of informal drawings
2. Copy of executed Declaration
3. Copy of executed Small Entity Statement
4. Preliminary Amendment
5. Two (2) return postcards.

The filing fee has been calculated as shown below:

(Col. 1)		(Col. 2)	SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
FOR	NO. FILED	NO. EXTRA	RATE	FEE		RATE	FEE
BASIC FEE				\$ 395.00	OR		\$ 790.00
TOTAL CLAIMS	4-20 =	* 0	X 11 =	0.00	OR	X 22 =	
INDEP. CLAIMS	4 -3 =	* 1	1 x 41 =	41.00	OR	X 82 =	
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED			+ 135 =	0.00	OR	+ 270 =	
			TOTAL	\$ 436.00	OR	TOTAL	

*If the difference in Col. 1 is less than zero, enter "0"
 in Col. 2

A check in the amount of **\$436.00** is enclosed.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038. A duplicate copy of this sheet is attached.

Date April 7, 1998

for Albert P. Halluin (Reg. No. 25,227) *P41,612*

PRODUCTION OF PEPTIDES IN PLANTS
AS VIRAL COAT PROTEIN FUSIONS

Thomas H. Turpen,
Stephen Reinl,
Laurence K. Grill

5

Field of the Invention

The present invention relates to the field of genetically engineered peptide production in plants, more specifically,
10 the invention relates to the use of tobamovirus vectors to express fusion proteins.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of
15 application 08/176,414, filed on December 29, 1993 which is a continuation-in-part of application Serial No. 07/997,733, filed December 30, 1992.

BACKGROUND OF THE INVENTION

20 Peptides are a diverse class of molecules having a variety of important chemical and biological properties. Some examples include; hormones, cytokines, immunoregulators, peptide-based enzyme inhibitors, vaccine antigens, adhesions, receptor binding domains, enzyme inhibitors and the like. The
25 cost of chemical synthesis limits the potential applications of synthetic peptides for many useful purposes such as large scale therapeutic drug or vaccine synthesis. There is a need for inexpensive and rapid synthesis of milligram and larger quantities of naturally-occurring polypeptides. Towards this
30 goal many animal and bacterial viruses have been successfully used as peptide carriers.

The safe and inexpensive culture of plants provides an improved alternative host for the cost-effective production of such peptides. During the last decade, considerable progress
35 has been made in expressing foreign genes in plants. Foreign proteins are now routinely produced in many plant species for modification of the plant or for production of proteins for

use after extraction. Animal proteins have been effectively produced in plants (reviewed in Krebbers et al., 1992).

Vectors for the genetic manipulation of plants have been derived from several naturally occurring plant viruses, including TMV (tobacco mosaic virus). TMV is the type member of the tobamovirus group. TMV has straight tubular virions of approximately 300 X 18 nm with a 4 nm-diameter hollow canal, consisting of approximately 2000 units of a single capsid protein wound helically around a single RNA molecule. Virion particles are 95% protein and 5% RNA by weight. The genome of TMV is composed of a single-stranded RNA of 6395 nucleotides containing five large ORFs. Expression of each gene is regulated independently. The virion RNA serves as the messenger RNA (mRNA) for the 5' genes, encoding the 126 kDa replicase subunit and the overlapping 183 kDa replicase subunit that is produced by read through of an amber stop codon approximately 5% of the time. Expression of the internal genes is controlled by different promoters on the minus-sense RNA that direct synthesis of 3'-coterminial subgenomic mRNAs which are produced during replication (Figure 1). A detailed description of tobamovirus gene expression and life cycle can be found, among other places, in Dawson and Lehto, Advances in Virus Research 38:307-342 (1991). It is of interest to provide new and improved vectors for the genetic manipulation of plants.

For production of specific proteins, transient expression of foreign genes in plants using virus-based vectors has several advantages. Products of plant viruses are among the highest produced proteins in plants. Often a viral gene product is the major protein produced in plant cells during virus replication. Many viruses are able to quickly move from an initial infection site to almost all cells of the plant. Because of these reasons, plant viruses have been developed into efficient transient expression vectors for foreign genes in plants. Viruses of multicellular plants are relatively small, probably due to the size limitation in the pathways that allow viruses to move to adjacent cells in the systemic

infection of entire plants. Most plant viruses have single-stranded RNA genomes of less than 10 kb. Genetically altered plant viruses provide one efficient means of transfecting plants with genes coding for peptide carrier fusions.

SUMMARY OF THE INVENTION

The present invention provides recombinant plant viruses that express fusion proteins that are formed by fusions between a plan viral coat protein and protein of interest. By infecting plant cells with the recombinant plant viruses of the invention, relatively large quantities of the protein of interest may be produced in the form of a fusion protein. The fusion protein encoded by the recombinant plant virus may have any of a variety of forms. The protein of interest may be fused to the amino terminus of the viral coat protein or the protein of interest may be fused to the carboxyl terminus of the viral coat protein. In other embodiments of the invention, the protein of interest may be fused internally to a coat protein. The viral coat fusion protein may have one or more properties of the protein of interest. The recombinant coat fusion protein may be used as an antigen for antibody development or to induce a protective immune response.

Another aspect of the invention is to provide polynucleotides encoding the genomes of the subject recombinant plant viruses. Another aspect of the invention is to provide the coat fusion proteins encoded by the subject recombinant plant viruses. Yet another embodiment of the invention is to provide plant cells that have been infected by the recombinant plant viruses of the invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Tobamovirus Gene Expression

The gene expression of tobamoviruses is diagrammed.

Figure 2. Plasmid Map of the TMV Transcription Vector pSNC004

0057016 040798 862040 " 97025660

The infectious RNA genome of the U1 strain of TMV is synthesized by T7 RNA polymerase in vitro from pSNC004 linearized with KpnI.

5 Figure 3. Diagram of Plasmid Constructions

Each step in the construction of plasmid DNAs encoding various viral epitope fusion vectors discussed in the examples is diagrammed.

10

Figure 4. Monoclonal Antibody (NVS3) Binding to TMV291

The reactivity of NVS3 to the malaria epitope present in TMV291 is measured in a standard ELISA.

15

Figure 5. Monoclonal Antibody (NYS1) Binding to TMV261

The reactivity of NYS1 to the malaria epitope present in TMV261 is measured in a standard ELISA.

20

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Definitions and Abbreviations

TMV: Tobacco mosaic tobamovirus

25

TMVCP: Tobacco mosaic tobamovirus coat protein

Viral Particles: High molecular weight aggregates of viral structural proteins with or without genomic nucleic acids

30

Virion: An infectious viral particle.

The Invention

The subject invention provides novel recombinant plant viruses that code for the expression of fusion proteins that consist of a fusion between a plant viral coat protein and a protein of interest. The recombinant plant viruses of the

invention provide for systemic expression of the fusion protein, by systemically infecting cells in a plant. Thus by employing the recombinant plant viruses of the invention, large quantities of a protein of interest may be produced.

5 The fusion proteins of the invention comprise two portions: (i) a plant viral coat protein and (ii) a protein of interest. The plant viral coat protein portion may be derived from the same plant viral coat protein that serves a coat protein for the virus from which the genome of the expression
10 vector is primarily derived, i.e., the coat protein is native with respect to the recombinant viral genome. Alternatively, the coat protein portion of the fusion protein may be heterologous, i.e., non-native, with respect to the recombinant viral genome. In a preferred embodiment of the
15 invention, the 17.5 KDa coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector. The protein of interest portion of the fusion protein for expression may consist of a peptide of virtually any amino acid sequence, provided that the protein of interest does not
20 significantly interfere with (1) the ability to bind to a receptor molecule, including antibodies and T cell receptor (2) the ability to bind to the active site of an enzyme (3) the ability to induce an immune response, (4) hormonal activity, (5) immunoregulatory activity, and (6) metal
25 chelating activity. The protein of interest portion of the subject fusion proteins may also possess additional chemical or biological properties that have not been enumerated. Protein of interest portions of the subject fusion proteins having the desired properties may be obtained by employing all
30 or part of the amino acid residue sequence of a protein known to have the desired properties. For example, the amino acid sequence of hepatitis B surface antigen may be used as a protein of interest portion of a fusion protein invention so as to produce a fusion protein that has antigenic properties
35 similar to hepatitis B surface antigen. Detailed structural and functional information about many proteins of interest are well known, this information may be used by the person of

09057016 "0407 98

ordinary skill in the art so as to provide for coat fusion proteins having the desired properties of the protein of interest. The protein of interest portion of the subject fusion proteins may vary in size from one amino acid residue 5 to over several hundred amino acid residues, preferably the sequence of interest portion of the subject fusion protein is less than 100 amino acid residues in size, more preferably, the sequence of interest portion is less than 50 amino acid residues in length. It will be appreciated by those of 10 ordinary skill in the art that, in some embodiments of the invention, the protein of interest portion may need to be longer than 100 amino acid residues in order to maintain the desired properties. Preferably, the size of the protein of interest portion of the fusion proteins of the invention is 15 minimized (but retains the desired biological/chemical properties), when possible.

While the protein of interest portion of fusion proteins of the invention may be derived from any of the variety of proteins, proteins for use as antigens are particularly 20 preferred. For example, the fusion protein, or a portion thereof, may be injected into a mammal, along with suitable adjuvants, so as to produce an immune response directed against the protein of interest portion of the fusion protein. The immune response against the protein of interest portion of 25 the fusion protein has numerous uses, such uses include, protection against infection, and the generation of antibodies useful in immunoassays.

The location (or locations) in the fusion protein of the invention where the viral coat protein portion is joined to 30 the protein of interest is referred to herein as the fusion joint. A given fusion protein may have one or two fusion joints. The fusion joint may be located at the carboxyl terminus of the coat protein portion of the fusion protein (joined at the amino terminus of the protein of interest 35 portion). The fusion joint may be located at the amino terminus of the coat protein portion of the fusion protein (joined to the carboxyl terminus of the protein of interest).

09057015 "040798

In other embodiments of the invention, the fusion protein may have two fusion joints. In those fusion proteins having two fusion joints, the protein of interest is located internal with respect to the carboxyl and amino terminal amino acid residues of the coat protein portion of the fusion protein, i.e., an internal fusion protein. Internal fusion proteins may comprise an entire plant virus coat protein amino acid residue sequence (or a portion thereof) that is "interrupted" by a protein of interest, i.e., the amino terminal segment of the coat protein portion is joined at a fusion joint to the amino terminal amino acid residue of the protein of interest and the carboxyl terminal segment of the coat protein is joined at a fusion joint to the amino terminal acid residue of the protein of interest.

15 When the coat fusion protein for expression is an internal fusion protein, the fusion joints may be located at a variety of sites within a coat protein. Suitable sites for the fusion joints may be determined either through routine systematic variation of the fusion joint locations so as to obtain an internal fusion protein with the desired properties. Suitable sites for the fusion jointly may also be determined by analysis of the three dimensional structure of the coat protein so as to determine sites for "insertion" of the protein of interest that do not significantly interfere with the structural and biological functions of the coat protein portion of the fusion protein. Detailed three dimensional structures of plant viral coat proteins and their orientation in the virus have been determined and are publicly available to a person of ordinary skill in the art. For example, a resolution model of the coat protein of Cucumber Green Mottle Mosaic Virus (a coat protein bearing strong structural similarities to other tobamovirus coat proteins) and the virus can be found in Wang and Stubbs J. Mol. Biol. 239:371-384 (1994). Detailed structural information on the virus and coat protein of Tobacco Mosaic Virus can be found, among other places in Namba et al, J. Mol. Biol. 208:307-325 (1989) and Pattanayek and Stubbs J. Mol. Biol. 228:516-528 (1992).

Knowledge of the three dimensional structure of a plant virus particle and the assembly process of the virus particle permits the person of ordinary skill in the art to design various coat protein fusion s of the invention, including
5 insertions, and partial substitutions. For example, if the protein of interest is of a hydrophilic nature, it may be appropriate to fuse the peptide to the TMVCP region known to be oriented as a surface loop region. Likewise, alpha helical segments that maintain subunit contacts might be substituted
10 for appropriate regions of the TMVCP helices or nucleic acid binding domains expressed in the region of the TMVCP oriented towards the genome.

Polynucleotide sequences encoding the subject fusion proteins may comprise a "leaky" stop codon at a fusion joint.
15 The stop codon may be present as the codon immediately adjacent to the fusion joint, or may be located close (e.g., within 9 bases) to the fusion joint. A leaky stop codon may be included in polynucleotides encoding the subject coat fusion proteins so as to maintain a desired ratio of fusion
20 protein to wild type coat protein. A "leaky" stop codon does not always result in translational termination and is periodically translated. The frequency of initiation or termination at a given start/stop codon is context dependent. The ribosome scans from the 5'-end of a messenger RNA for the
25 first ATG codon. If it is in a non-optimal sequence context, the ribosome will pass, some fraction of the time, to the next available start codon and initiate translation downstream of the first. Similarly, the first termination codon encountered during translation will not function 100% of the time if it is
30 in a particular sequence context. Consequently, many naturally occurring proteins are known to exist as a population having heterogeneous N and/or C terminal extensions. Thus by including a leaky stop codon at a fusion joint coding region in a recombinant viral vector encoding a
35 coat fusion protein, the vector may be used to produce both a fusion protein and a second smaller protein, e.g., the viral coat protein. A leaky stop codon may be used at, or proximal

to, the fusion joints of fusion proteins in which the protein of interest portion is joined to the carboxyl terminus of the coat protein region, whereby a single recombinant viral vector may produce both coat fusion proteins and coat proteins.

5 Additionally, a leaky start codon may be used at or proximal to the fusion joints of fusion proteins in which the protein of interest portion is joined to the amino terminus of the coat protein region, whereby a similar result is achieved. In the case of TMVCP, extensions at the N and C terminus are at
10 the surface of viral particles and can be expected to project away from the helical axis. An example of a leaky stop sequence occurs at the junction of the 126/183 kDa reading frames of TMV and was described over 15 years ago (Pelham, H.R.B., 1978). Skuzeski et al. (1991) defined necessary 3'
15 context requirements of this region to confer leakiness of termination on a heterologous protein marker gene (β -glucuronidase) as CAR-YYA (C=cytidine, A=adenine, Y=pyrimidine).

In another embodiment of the invention, the fusion joints
20 on the subject coat fusion proteins are designed so as to comprise an amino acid sequence that is a substrate for protease. By providing a coat fusion protein having such a fusion joint, the protein of interest may be conveniently derived from the coat protein fusion by using a suitable
25 proteolytic enzyme. The proteolytic enzyme may contact the fusion protein either in vitro or in vivo.

The expression of the subject coat fusion proteins may be driven by any of a variety of promoters functional in the genome of the recombinant plant viral vector. In a preferred
30 embodiment of the invention, the subject fusion proteins are expressed from plant viral subgenomic promoters using vectors as described in U.S. Patent 5,316,931.

Recombinant DNA technologies have allowed the life cycle of numerous plant RNA viruses to be extended artificially
35 through a DNA phase that facilitates manipulation of the viral genome. These techniques may be applied by the person ordinary skill in the art in order make and use recombinant

plant viruses of the invention. The entire cDNA of the TMV genome was cloned and functionally joined to a bacterial promoter in an *E. coli* plasmid (Dawson et al., 1986).

Infectious recombinant plant viral RNA transcripts may also be produced using other well known techniques, for example, with the commercially available RNA polymerases from T7, T3 or SP6. Precise replicas of the virion RNA can be produced in vitro with RNA polymerase and dinucleotide cap, m7GpppG. This not only allows manipulation of the viral genome for reverse genetics, but it also allows manipulation of the virus into a vector to express foreign genes. A method of producing plant RNA virus vectors based on manipulating RNA fragments with RNA ligase has proved to be impractical and is not widely used (Pelcher, L.E., 1982). Detailed information on how to make and use recombinant RNA plant viruses can be found, among other places in U.S. patent 5,316,931 (Donson et al.), which is herein incorporated by reference. The invention provides for polynucleotide encoding recombinant RNA plant vectors for the expression of the subject fusion proteins. The invention also provides for polynucleotides comprising a portion or portions of the subject vectors. The vectors described in U.S. Patent 5,316,931 are particularly preferred for expressing the fusion proteins of the invention.

In addition to providing the described viral coat fusion proteins, the invention also provides for virus particles that comprise the subject fusion proteins. The coat of the virus particles of the invention may consist entirely of coat fusion protein. In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied. As tobamovirus coat proteins may self-assemble into virus particles, the virus particles of the invention may be assembled either in vivo or in vitro. The virus particles may also be conveniently disassembled using well known techniques so as to simplify the purification of the subject fusion proteins, or portions thereof.

09057016 "040798

The invention also provides for recombinant plant cells comprising the subject coat fusion proteins and/or virus particles comprising the subject coat fusion proteins. These plant cells may be produced either by infecting plant cells 5 (either in culture or in whole plants) with infectious virus particles of the invention or with polynucleotides encoding the genomes of the infectious virus particle of the invention. The recombinant plant cells of the invention having many uses. Such uses include serving as a source for the fusion coat 10 proteins of the invention.

The protein of interest portion of the subject fusion proteins may comprise many different amino acid residue sequences, and accordingly may differ in possible biological/chemical properties however, in a preferred 15 embodiment of the invention the protein of interest portion of the fusion protein is useful as a vaccine antigen. The surface of TMV particles and other tobamoviruses contain continuous epitopes of high antigenicity and segmental mobility thereby making TMV particles especially useful in 20 producing a desired immune response. These properties make the virus particles of the invention especially useful as carriers in the presentation of foreign epitopes to mammalian immune systems.

While the recombinant RNA viruses of the invention may be 25 used to produce numerous coat fusion proteins for use as vaccine antigens or vaccine antigen precursors, it is of particular interest to provide vaccines against malaria. Human malaria is caused by the protozoan species *Plasmodium falciparum*, *P. vivax*, *P. ovale* and *P. malariae* and is 30 transmitted in the sporozoite form by *Anopheles* mosquitos. Control of this disease will likely require safe and stable vaccines. Several peptide epitopes expressed during various stages of the parasite life cycle are thought to contribute to the induction of protective immunity in partially resistant 35 individuals living in endemic areas and in individuals experimentally immunized with irradiated sporozoites.

When the fusion proteins of the invention, portions thereof, or viral particles comprising the fusion proteins are used *in vivo*, the proteins are typically administered in a composition comprising a pharmaceutical carrier. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivery of the desired compounds to the body. Sterile water, alcohol, fats, waxes and inert solids may be included in the carrier. Pharmaceutically accepted adjuvants (buffering agents, dispersing agent) may also be incorporated into the pharmaceutical composition. Additionally, when the subject fusion proteins, or portion thereof, are to be used for the generation of an immune response, protective or otherwise, formulation for administration may comprise one or immunological adjuvants in order to stimulate a desired immune response.

When the fusion proteins of the invention, or portions thereof, are used *in vivo*, they may be administered to a subject, human or animal, in a variety of ways. The pharmaceutical compositions may be administered orally or parenterally, i.e., subcutaneously, intramuscularly or intravenously. Thus, this invention provides compositions for parenteral administration which comprise a solution of the fusion protein (or derivative thereof) or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycerine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentration of fusion protein (or portion thereof) in these formulations can vary widely depending on the specific amino acid sequence of the subject proteins and

the desired biological activity, e.g., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Actual methods for preparing parenterally administrable compositions and adjustments necessary for administration to subjects will be known or apparent to those skilled in the art and are described in more detail in, for example, *Remington's Pharmaceutical Science*, current edition, Mack Publishing Company, Easton, Pa, which is incorporated herein by reference.

The invention having been described above, may be better understood by reference to the following examples. The examples are offered by way of illustration and are not intended to be interpreted as limitations on the scope of the invention.

EXAMPLES

20 Biological Deposits

The following present examples are based on a full length insert of wild type TMV (U1 strain) cloned in the vector pUC18 with a T7 promoter sequence at the 5'-end and a KpnI site at the 3'-end (pSNC004, Figure 2) or a similar plasmid pTMV304.

25 Using the polymerase chain reaction (PCR) technique and primers WD29 (SEQ ID NO: 1) and D1094 (SEQ ID NO: 2) a 277 XmaI/HindIII amplification product was inserted with the 6140 bp XmaI/KpnI fragment from pTMV304 between the KpnI and HindIII sites of the common cloning vector pUC18 to create

30 pSNC004. The plasmid pTMV304 is available from the American Type Culture Collection, Rockville, Maryland (ATCC deposit 45138). The genome of the wild type TMV strain can be synthesized from pTMV304 using the SP6 polymerase, or from pSNC004 using the T7 polymerase. The wild type TMV strain can

35 also be obtained from the American Type Culture Collection, Rockville, Maryland (ATCC deposit No. PV135). The plasmid pBGC152, Kumagai, M., et al., (1993), is a derivative of

pTMV304 and is used only as a cloning intermediate in the examples described below. The construction of each plasmid vector described in the examples below is diagrammed in Figure 3.

5

Example 1.

Propagation and purification of the U1 strain of TMV

The TMVCP fusion vectors described in the following examples are based on the U1 or wild type TMV strain and are therefore compared to the parental virus as a control. *Nicotiana tabacum* cv Xanthi (hereafter referred to as tobacco) was grown 4-6 weeks after germination, and two 4-8 cm expanded leaves were inoculated with a solution of 50 µg/ml TMV U1 by pipetting 100 µl onto carborundum dusted leaves and lightly abrading the surface with a gloved hand. Six tobacco plants were grown for 27 days post inoculation accumulating 177 g fresh weight of harvested leaf biomass not including the two lower inoculated leaves. Purified TMV U1 Sample ID No. TMV204.B4 was recovered (745 mg) at a yield of 4.2 mg of virion per gram of fresh weight by two cycles of differential centrifugation and precipitation with PEG according to the method of Gooding et al. (1967). Tobacco plants infected with TMV U1 accumulated greater than 230 micromoles of coat protein per kilogram of leaf tissue.

25

Example 2.

Production of a malarial B-cell epitope genetically fused to the surface loop region of the TMVCP

The monoclonal antibody NVS3 was made by immunizing a mouse with irradiated *P. vivax* sporozoites. NVS3 mAb passively transferred to monkeys provided protective immunity to sporozoite infection with this human parasite. Using the technique of epitope-scanning with synthetic peptides, the exact amino acid sequence present on the *P. vivax* sporozoite surface and recognized by NVS3 was defined as AGDR (Seq ID No. P1). The epitope AGDR is contained within a repeating unit of

the circumsporozoite (CS) protein (Charoenvit et al., 1991a), the major immunodominant protein coating the sporozoite. Construction of a genetically modified tobamovirus designed to carry this malarial B-cell epitope fused to the surface of virus particles is set forth herein.

Construction of plasmid pBGC291. The 2.1 kb EcoRI-PstI fragment from pTMV204 described in Dawson, W., et al. (1986) was cloned into pBstSK- (Stratagene Cloning Systems) to form pBGC11. A 0.27 kb fragment of pBGC11 was PCR amplified using the 5' primer TB2ClaI5' (SEQ ID NO: 3) and the 3' primer CP.ME2+ (SEQ ID NO: 4). The 0.27 kb amplified product was used as the 5' primer and C/OAvrII (SEQ ID NO: 5) was the 3' primer for PCR amplification. The amplified product was cloned into the SmaI site of pBstKS+ (Stratagene Cloning Systems) to form pBGC243.

To eliminate the BstXI and SacII sites from the polylinker, pBGC234 was formed by digesting pBstKS+ (Stratagene Cloning Systems) with BstXI followed by treatment with T4 DNA Polymerase and self-ligation. The 1.3 kb HindIII-KpnI fragment of pBGC304 was cloned into pBGC234 to form pBGC235. pBGC304 is also named pTMV304 (ATCC deposit 45138).

The 0.3 kb PacI-AccI fragment of pBGC243 was cloned into pBGC235 to form pBGC244. The 0.02 kb polylinker fragment of pBGC243 (SmaI-EcoRV) was removed to form pBGC280. A 0.02 kb synthetic PstI fragment encoding the *P. vivax* AGDR repeat was formed by annealing AGDR3p (SEQ ID NO: 6) with AGDR3m (SEQ ID NO: 7) and the resulting double stranded fragment was cloned into pBGC280 to form pBGC282. The 1.0 kb NcoI-KpnI fragment of pBGC282 was cloned into pSNC004 to form pBGC291.

The coat protein sequence of the virus TMV291 produced by transcription of plasmid pBGC291 in vitro is listed in (SEQ ID NO: 16) The epitope (AGDR)3 is calculated to be approximately 6.2% of the weight of the virion.

Propagation and purification of the epitope expression vector. Infectious transcripts were synthesized from KpnI-linearized pBGC291 using T7 RNA polymerase and cap

(7mGpppG) according to the manufacturer (New England Biolabs).

An increased quantity of recombinant virus was obtained by passaging and purifying Sample ID No. TMV291.1B1 as described in example 1. Twenty tobacco plants were grown for 5 29 days post inoculation, accumulating 1060 g fresh weight of harvested leaf biomass not including the two lower inoculated leaves. Purified Sample ID TMV291.1B2 was recovered (474 mg) at a yield of 0.4 mg virion per gram of fresh weight. Therefore, 25 µg of 12-mer peptide was obtained per gram of 10 fresh weight extracted. Tobacco plants infected with TMV291 accumulated greater than 21 micromoles of peptide per kilogram of leaf tissue.

Product analysis. The conformation of the epitope AGDR contained in the virus TMV291 is specifically recognized 15 by the monoclonal antibody NVS3 in ELISA assays (Figure 4). By Western blot analysis, NVS3 cross-reacted only with the TMV291 cp fusion at 18.6 kD and did not cross-react with the wild type or cp fusion present in TMV261. The genomic sequence of the epitope coding region was confirmed by 20 directly sequencing viral RNA extracted from Sample ID No. TMV291.1B2.

Example 3.

25 Production of a malarial B-cell epitope genetically fused to the C terminus of the TMVCP

Significant progress has been made in designing effective subunit vaccines using rodent models of malarial disease caused by nonhuman pathogens such as *P. yoelii* or *P. berghei*. The monoclonal antibody NYS1 recognizes the repeating epitope 30 QGPGAP (SEQ ID NO: 18), present on the CS protein of *P. yoelii*, and provides a very high level of immunity to sporozoite challenge when passively transferred to mice (Charoenvit, Y., et al. 1991b). Construction of a genetically modified tobamovirus designed to carry this malarial B-cell 35 epitope fused to the surface of virus particles is set forth herein.

Construction of plasmid pBGC261. A 0.5 kb fragment of pBGC11, was PCR amplified using the 5' primer TB2ClaI5' (SEQ ID NO: 3) and the 3' primer C/OAvrII (SEQ ID NO: 5). The amplified product was cloned into the SmaI site of pBstKS+ 5 (Stratagene Cloning Systems) to form pBGC218.

pBGC219 was formed by cloning the 0.15 kb AccI-NsiI fragment of pBGC218 into pBGC235. A 0.05 kb synthetic AvrII fragment was formed by annealing PYCS.1p (SEQ ID NO: 8) with PYCS.1m (SEQ ID NO: 9) and the resulting double stranded 10 fragment, encoding the leaky-stop signal and the *P. yoelii* B-cell malarial epitope, was cloned into the AvrII site of pBGC219 to form pBGC221. The 1.0 kb NcoI-KpnI fragment of pBGC221 was cloned into pBGC152 to form pBGC261.

The virus TMV261, produced by transcription of plasmid 15 pBGC261 in vitro, contains a leaky stop signal at the C terminus of the coat protein gene and is therefore predicted to synthesize wild type and recombinant coat proteins at a ratio of 20:1. The recombinant TMVCP fusion synthesized by TMV261 is listed in (SEQ ID NO: 19) with the stop codon 20 decoded as the amino acid Y (amino acid residue 160). The wild type sequence, synthesized by the same virus, is listed in (SEQ ID NO: 21). The epitope (QGPGAP)₂ is calculated to be present at 0.3% of the weight of the virion.

Propagation and purification of the epitope expression 25 vector. Infectious transcripts were synthesized from KpnI-linearized pBGC261 using SP6 RNA polymerase and cap (7mGpppG) according to the manufacturer (Gibco/BRL Life Technologies).

An increased quantity of recombinant virus was obtained 30 by passaging and purifying Sample ID No. TMV261.B1b as described in example 1. Six tobacco plants were grown for 27 days post inoculation, accumulating 205 g fresh weight of harvested leaf biomass not including the two lower inoculated leaves. Purified Sample ID No. TMV261.1B2 was recovered (252 35 mg) at a yield of 1.2 mg virion per gram of fresh weight. Therefore, 4 µg of 12-mer peptide was obtained per gram of fresh weight extracted. Tobacco plants infected with TMV261

accumulated greater than 3.9 micromoles of peptide per kilogram of leaf tissue.

Product analysis. The content of the epitope QGPGAP in the virus TMV261 was determined by ELISA with monoclonal antibody NYS1 (Figure 5). From the titration curve, 50 ug/ml of TMV261 gave the same O.D. reading (1.0) as 0.2 ug/ml of (QGPGAP)2. The measured value of approximately 0.4% of the weight of the virion as epitope is in good agreement with the calculated value of 0.3%. By Western blot analysis, NYS1 cross-reacted only with the TMV261 cp fusion at 19 kD and did not cross-react with the wild type cp or cp fusion present in TMV291. The genomic sequence of the epitope coding region was confirmed by directly sequencing viral RNA extracted from Sample ID. No. TMV261.1B2.

15

Example 4.

Production of a malarial CTL epitope genetically fused to the C terminus of the TMVCP

Malarial immunity induced in mice by irradiated sporozoites of *P. yoelii* is also dependent on CD8+ T lymphocytes. Clone B is one cytotoxic T lymphocyte (CTL) cell clone shown to recognize an epitope present in both the *P. yoelii* and *P. berghei* CS proteins. Clone B recognizes the following amino acid sequence; SYVPSAEQILEFVKQISSQ (SEQ ID NO: 23) and when adoptively transferred to mice protects against infection from both species of malaria sporozoites (Weiss et al., 1992). Construction of a genetically modified tobamovirus designed to carry this malarial CTL epitope fused to the surface of virus particles is set forth herein.

Construction of plasmid pBGC289. A 0.5 kb fragment of pBGC11 was PCR amplified using the 5' primer TB2ClaI5' (SEQ ID NO: 3) and the 3' primer C/-5AvrII (SEQ ID NO: 10). The amplified product was cloned into the SmaI site of pBstKS+ (Stratagene Cloning Systems) to form pBGC214.

pBGC215 was formed by cloning the 0.15 kb AccI-NsiI fragment of pBGC214 into pBGC235. The 0.9 kb NcoI-KpnI fragment from pBGC215 was cloned into pBGC152 to form pBGC216.

09057016 "040398

A 0.07 kb synthetic fragment was formed by annealing PYCS.2p (SEQ ID NO: 11) with PYCS.2m (SEQ ID NO: 12) and the resulting double stranded fragment, encoding the *P. yoelii* CTL malarial epitope, was cloned into the AvrII site of pBGC215 made blunt ended by treatment with mung bean nuclease and creating a unique AatII site, to form pBGC262. A 0.03 kb synthetic AatII fragment was formed by annealing TLS.1EXP (SEQ ID NO: 13) with TLS.1EXM (SEQ ID NO: 14) and the resulting double stranded fragment, encoding the leaky-stop sequence and a stuffer sequence used to facilitate cloning, was cloned into AatII digested pBGC262 to form pBGC263. pBGC262 was digested with AatII and ligated to itself removing the 0.02 kb stuffer fragment to form pBGC264. The 1.0 kb NcoI-KpnI fragment of pBGC264 was cloned into pSNC004 to form pBGC289.

15 The virus TMV289 produced by transcription of plasmid pBGC289 in vitro, contains a leaky stop signal resulting in the removal of four amino acids from the C terminus of the wild type TMV coat protein gene and is therefore predicted to synthesize a truncated coat protein and a coat protein with a CTL epitope fused at the C terminus at a ratio of 20:1. The recombinant TMVCP/CTL epitope fusion present in TMV289 is listed in SEQ ID NO: 25 with the stop codon decoded as the amino acid Y (amino acid residue 156). The wild type sequence minus four amino acids from the C terminus is listed in SEQ ID NO: 26. The amino acid sequence of the coat protein of virus TMV216 produced by transcription of the plasmid pBGC216 in vitro, is also truncated by four amino acids. The epitope SYVPSAEQILEFVKQISSQ (SEQ ID NO:23) is calculated to be present at approximately 0.5% of the weight of the virion using the same assumptions confirmed by quantitative ELISA analysis of the readthrough properties of TMV261 in example 3.

30 Propagation and purification of the epitope expression vector. Infectious transcripts were synthesized from KpnI-linearized pBGC289 using T7 RNA polymerase and cap (7mGpppG) according to the manufacturer (New England Biolabs).

35 An increased quantity of recombinant virus was obtained by passaging Sample ID No. TMV289.11B1a as described in

example 1. Fifteen tobacco plants were grown for 33 days post inoculation accumulating 595 g fresh weight of harvested leaf biomass not including the two lower inoculated leaves.

Purified Sample ID. No. TMV289.11B2 was recovered (383 mg) at
5 a yield of 0.6 mg virion per gram of fresh weight. Therefore,
3 μ g of 19-mer peptide was obtained per gram of fresh weight
extracted. Tobacco plants infected with TMV289 accumulated
greater than 1.4 micromoles of peptide per kilogram of leaf
tissue.

- 10 Product analysis. Partial confirmation of the sequence
of the epitope coding region of TMV289 was obtained by
restriction digestion analysis of PCR amplified cDNA using
viral RNA isolated from Sample ID. No. TMV289.11B2. The
presence of proteins in TMV289 with the predicted mobility of
15 the cp fusion at 20 kD and the truncated cp at 17.1 kD was
confirmed by denaturing polyacrylamide gel electrophoresis.

LITERATURE CITED

- 20 Ahlquist, P. G., and French, R. C. 1986. RNA transformation
vector. European Patent Appl. 194,809.

Bruening, G., 1978. Comovirus group, C.M.I./A.A.B.
Descriptions of plant viruses, No. 199. Wm. Culross and Son
25 Ltd., Coupar Angus, Perthshire, Scotland.

- Butler, P. J. G., Mayo, M. A. 1987. Molecular architecture and
assembly of tobacco mosaic virus particles, The molecular
biology of the positive strand RNA viruses. (D. J. Rowlands,
30 M. A. Mayo, and B. W. J. Mahy, eds.), Academic Press, London.
pp. 237-257.

- Charoenvit, Y., Collins, W.E., Jones, T.R., Millet, P., Yuan,
L., Beaudoin, R.L., Broderson, J.R., and Hoffman, S.L. 1991a.
35 Inability of malaria vaccine to induce antibodies to a
protective epitope within its sequence. Science 251:668-671.

Charoenvit, Y., Mellouk, S., Cole, C., Bechara, R., Leef, M.F., Sedegah, M., Yuan, L., Robey, F.A., Beaudoin, R.L., and Hoffman, S.L. 1991b. Monoclonal, but not polyclonal, antibodies protect against *Plasmodium yoelii* sporozoites. J. Immunol. 146:1020-1025.

Dawson, W. O., Beck, D. L., Knorr, D. A., and Grantham, G. L. 1986. cDNA cloning of the complete genome of tobacco mosaic virus and production of infectious transcripts. Proc. Natl. Acad. Sci. USA 83:1832-1836.

Dawson, W. O., Bubrick, P., and Grantham, G. L. 1988. Modifications of the tobacco mosaic virus coat protein gene affecting replication, movement, and symptomatology. Phytopathology 78:783-789.

Dawson, W. O., Lewandowski, D. J., Hilf, M. E., Bubrick, P., Raffo, A. J., Shaw, J. J., Grantham, G. L., and Desjardins, P. R. 1989. A tobacco mosaic virus-hybrid expresses and loses an added gene. Virology 172:285-292.

Donson, J., Kearney, C. M., Hilf, M. E., and Dawson, W. O. 1991. Systemic expression of a bacterial gene by a tobacco mosaic virus-based vector. Proc. Natl. Acad. Sci. USA 88:7204-7208.

Donson, J., Dawson, W. O., Grantham, G. L., Turpen, T. H., Turpen, A. M., Garger, S. J., and Grill, L. K. 1992. Recombinant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes. U.S. Patent Appl. Serial No. 923,692.

French, R., Janda, M., and Ahlquist, P. 1986. Bacterial gene inserted in an engineered RNA virus: Efficient expression in monocotyledonous plant cells. Science 231:1294-1297.

Gibbs, A.J. 1977. Tobamovirus group, C.M.I./A.A.B.
Descriptions of plant viruses, No. 184. Wm. Culross and Son
Ltd., Coupar Angus, Perthshire, Scotland.

- 5 Goelet, P., Lomonossoff, G.P., Butler P.J.G., Akam, M.E., and
Karn, J. 1982. Nucleotide sequence of tobacco mosaic virus
RNA. Proc. Natl. Acad. Sci. USA 79:5818-5822.

Gooding, Jr., G.V., and Hebert, T.T. 1967. A simple technique
10 for purification of tobacco mosaic virus in large quantities.
Phytopathology 57:1285.

- Hamamoto, H., Hashida, E., Matsunaga, Y., Nakagawa, N.,
Nakanishi, N., Okada, Y., Sugiyama, Y., and Tsuchimoto, S.
15 1993a. Plant virus vector for foreign gene expression -
contains foreign gene down stream of viral coat protein gene,
linked by read-through sequence. PCT Patent Application WO
93/JP408.

- 20 Hamamoto, H., Sugiyama, Y., Nakagawa, N., Hashida, E.,
Matsunaga, Y., Takemoto, S., Watanabe Y., and Okada, Y. 1993b.
A new tobacco mosaic virus vector and its use for the systemic
production of angiotensin-I-converting enzyme inhibitor in
transgenic tobacco and tomato. Bio/Technology 11:930-932.

- 25 Haynes, J.R., Cunningham, J., von Seefried, A., Lennick, M.,
Garvin, R.T., and Shen, S.-H. 1986. Development of a
genetically-engineered, candidate polio vaccine employing the
self-assembling properties of the tobacco mosaic virus coat
30 protein. Bio/Technology 4:637-641.

James, E.A., Garvin, R.T., and Haynes, J.R. 1985.
Multispecific immunogenic proteins. European Patent
Application, 174,759.

- 35 Krebbers, E., Bosch, D., and Vandekerckhove, J. 1992.
Prospects and progress in the production of foreign proteins

and peptides in plants, Plant Protein Engineering. (P. R. Shewry and S. Gutteridge, eds.), Cambridge University Press, Cambridge. pp. 316-324.

- 5 Kumagai, M. H., Turpen, T. H., Weinzettl, N., della-Cioppa, G., Turpen, A. M., Donson, J., Hilf, M. E., Grantham, G. L., Dawson, W. O., Chow, T. P., Piatak Jr., M., and Grill, L. K. 1993. Rapid, high level expression of biologically active α -trichosanthin in transfected plants by a novel RNA viral
10 vector. Proc. Natl. Acad. Sci. USA 90:427-430.

Lomonossoff, G. P., and Johnson, J. E. 1992. Modified plant viruses as vectors. PCT Application WO 92/18618.

- 15 Mason, H.S., Lam, D. M-K., and Arntzen, C.J. 1992. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA 89:11745-11749.

- Okada, Y., and Han, K. 1986. Plant virus RNA vector. Japanese
20 Patent Application 61/158443.

Okada, Y., and Takamatsu, N. 1988. A plant virus RNA vector. Japanese Patent Application 63/200789.

- 25 Pelcher, L. E., Halasa, M. C. 1982. An RNA plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom. European Patent Appl. 067,553.

- 30 Pelham, H.R.B. 1978. Leaky UAG termination codon in tobacco mosaic virus RNA. Nature 272:469-471.

- Skuzeski, J.M., Nichols, L.M., Gesteland, R.F., and Atkins, J.F. 1991. The signal for a leaky UAG stop codon in several
35 plant viruses includes the two downstream codons. J. Mol. Biol. 218:365-373.

Takamatsu, N., Ishikawa, M., Meshi, T., and Okada, Y. 1987.
Expression of bacterial chloramphenicol acetyltransferase gene
in tobacco plants mediated by TMV-RNA. EMBO J. 6:307-311.

5 Takamatsu, N., Watanabe, Y., Yanagi, H., Meshi, T., Shiba, T.,
and Okada, Y. 1990. Production of enkephalin in tobacco
protoplasts using tobacco mosaic virus RNA vector. FEBS Lett.
269:73-76.

10 Turpen, T.H., and Grill, L.K. April 4, 1989. New products
through viral coat protein modification. Biosource Genetics
Corporation, Record of Invention, First Written Disclosure.

Usha, R., Rohll, J.B., Spall, V.E., Shanks, M., Maule, A.J.,
15 Johnson, J.E., and Lomonossoff, G. P. 1993. Expression of an
animal virus antigenic site on the surface of a plant virus
particle. Virology 197:366-374.

van Kammen, A., and de Jager, C.P. 1978. Cowpea mosaic virus,
20 C.M.I./A.A.B. Descriptions of plant viruses, No. 197. Wm.
Culross and Son Ltd., Coupar Angus, Perthshire, Scotland.

Weiss, W.R., Berzofsky, J.A., Houghten, R.A., Sedegah, M.,
Hollindale, M., and Hoffman, S.L. 1992. A T cell clone
25 directed at the circumsporozoite protein which protects mice
against both Plasmodium yoelii and Plasmodium berghei. J.
Immunol. 149:2103-2109.

Zaitlin, M., and Israel, H.W. 1975. Tobacco mosaic virus (type
30 strain), C.M.I./A.A.B. Descriptions of plant viruses, No. 151.
Wm. Culross and Son Ltd., Coupar Angus, Perthshire, Scotland.

Incorporation by Reference

All patents, patents applications, and publications cited
35 are incorporated herein by reference.

Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-
5 described makes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

10

15

20

25

30

35

05057016 040798

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Turpen, Thomas H.
Reinl, Stephen
Grill, Laurence K.
- (ii) TITLE OF INVENTION: Production of Peptides in Plants as
Viral Coat Protein Fusions
- (iii) NUMBER OF SEQUENCES: 27
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US To be assigned
(B) FILING DATE: 14-OCT-1994
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Halluin, Albert P.
(B) REGISTRATION NUMBER: 25,227
(C) REFERENCE/DOCKET NUMBER: 8129-087
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415-854-3660
(B) TELEFAX: 415-854-3694
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGAATTCAAG CTTAATACGA CTCCTATAG TATTTTACA ACAATTACC

49

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCTTCATGTA AACCTCTC

18

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TAATCGATGA TGATTCCGAG GCTAC

25

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAAGTCTCTG TCTCCTGCAG GGAACCTAAC AGTTAC

36

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATTATGCATC TTGACTACCT AGGTTGCAGG ACCAGA

36

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGCGATCGGG CTGGTGACCG TGCA

24

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGGTCACCAG CCCGATCGCC TGCA

24

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 45 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTAGCAATTA CAAGGTCCAG GTGCACCTCA AGGTCCTGGA GCTCC

45

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 45 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTAGGGAGCT CCAGGACCTT GAGGTGCACC TGGACCTTGT AATTG

45

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATTATGCATC TTGACTACCT AGGTCCAAAC CAAAC 35

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTCATATGTT CCATCTGCAG AGCAGATCTT GGAATTCGTT AAGCAAATCT CGAGTCAGTA 60

ACTATA 66

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TATAGTTACT GACTCGAGAT TTGCTTAACG AATTCCAAGA TCTGCTCTGC AGATGGAACA 60

TATGAC 66

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGACCTAGGT GATGACGTCA TAGCAATTAA CGT

33

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TAATTGCTAT GACGTCATCA CCTAGGTCGA CGT

33

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ala Gly Asp Arg
1

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 510 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: pBGC291 Fusion
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..510

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATG	TCT	TAC	AGT	ATC	ACT	ACT	CCA	TCT	CAG	TTC	GTG	TTC	TTG	TCA	TCA	
Met	Ser	Tyr	Ser	Ile	Thr	Thr	Pro	Ser	Gln	Phe	Val	Phe	Leu	Ser	Ser	
1					5				10					15		
GCG	TGG	GCC	GAC	CCA	ATA	GAG	TTA	ATT	AAT	TTA	TGT	ACT	AAT	GCC	TTA	
Ala	Trp	Ala	Asp	Pro	Ile	Glu	Leu	Ile	Asn	Leu	Cys	Thr	Asn	Ala	Leu	
			20					25					30			

48

96

GGA AAT CAG TTT CAA ACA CAA CAA GCT CGA ACT GTC GTT CAA AGA CAA	144
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
TTC AGT GAG GTG TGG AAA CCT TCA CCA CAA GTA ACT GTT AGG TTC CCT	192
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
GCA GGC GAT CGG GCT GGT GAC CGT GCA GGA GAC AGA GAC TTT AAG GTG	240
Ala Gly Asp Arg Ala Gly Asp Arg Ala Gly Asp Arg Asp Phe Lys Val	
65 70 75 80	
TAC AGG TAC AAT GCG GTA TTA GAC CCG CTA GTC ACA GCA CTG TTA GGT	288
Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu Val Thr Ala Leu Leu Gly	
85 90 95	
GCA TTC GAC ACT AGA AAT AGA ATA ATA GAA GTT GAA AAT CAG GCG AAC	336
Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu Val Glu Asn Gln Ala Asn	
100 105 110	
CCC ACG ACT GCC GAA ACG TTA GAT GCT ACT CGT AGA GTA GAC GAC GCA	384
Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr Arg Arg Val Asp Asp Ala	
115 120 125	
ACG GTG GCC ATA AGG AGC GCG ATA AAT AAT TTA ATA GTA GAA TTG ATC	432
Thr Val Ala Ile Arg Ser Ala Ile Asn Asn Leu Ile Val Glu Leu Ile	
130 135 140	
AGA GGA ACC GGA TCT TAT AAT CGG AGC TCT TTC GAG AGC TCT TCT GGT	480
Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser Phe Glu Ser Ser Ser Gly	
145 150 155 160	
TTG GTT TGG ACC TCT GGT CCT GCA ACT TGA	510
Leu Val Trp Thr Ser Gly Pro Ala Thr	
165 170	

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 169 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: pBGC291 Fusion

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	

Ala Gly Asp Arg Ala Gly Asp Arg Ala Gly Asp Arg Asp Phe Lys Val
65 70 75 80
Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu Val Thr Ala Leu Leu Gly
85 90 95
Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu Val Glu Asn Gln Ala Asn
100 105 110
Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr Arg Arg Val Asp Asp Ala
115 120 125
Thr Val Ala Ile Arg Ser Ala Ile Asn Asn Leu Ile Val Glu Leu Ile
130 135 140
Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser Phe Glu Ser Ser Ser Gly
145 150 155 160
Leu Val Trp Thr Ser Gly Pro Ala Thr
165

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gln Gly Pro Gly Ala Pro
1 5

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 525 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: pBGC261 Leaky Stop

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..525

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATG TCT TAC AGT ATC ACT ACT CCA TCT CAG TTC GTG TTC TTG TCA TCA
Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser
1 5 10 15

48

GCG TGG GCC GAC CCA ATA GAG TTA ATT AAT TTA TGT ACT AAT GCC TTA	96
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
GGA AAT CAG TTT CAA ACA CAA CAA GCT CGA ACT GTC GTT CAA AGA CAA	144
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
TTC AGT GAG GTG TGG AAA CCT TCA CCA CAA GTA ACT GTT AGG TTC CCT	192
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
GAC AGT GAC TTT AAG GTG TAC AGG TAC AAT GCG GTA TTA GAC CCG CTA	240
Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu	
65 70 75 80	
GTC ACA GCA CTG TTA GGT GCA TTC GAC ACT AGA AAT AGA ATA ATA GAA	288
Val Thr Ala Leu Gly Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu	
85 90 95	
GTT GAA AAT CAG GCG AAC CCC ACG ACT GCC GAA ACG TTA GAT GCT ACT	336
Val Glu Asn Gln Ala Asn Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr	
100 105 110	
CGT AGA GTA GAC GAC GCA ACG GTG GCC ATA AGG AGC GCG ATA AAT AAT	384
Arg Arg Val Asp Asp Ala Thr Val Ala Ile Arg Ser Ala Ile Asn Asn	
115 120 125	
TTA ATA GTA GAA TTG ATC AGA GGA ACC GGA TCT TAT AAT CGG AGC TCT	432
Leu Ile Val Glu Leu Ile Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser	
130 135 140	
TTC GAG AGC TCT TCT GGT TTG GTT TGG ACC TCT GGT CCT GCA ACC TAG	480
Phe Glu Ser Ser Ser Gly Leu Val Trp Thr Ser Gly Pro Ala Thr Tyr	
145 150 155 160	
CAA TTA CAA GGT CCA GGT GCA CCT CAA GGT CCT GGA GCT CCC TA	525
Gln Leu Gln Gly Pro Gly Ala Pro Gln Gly Pro Gly Ala Pro	
165 170 175	

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: pBGC261 Leaky Stop

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	

Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro
 50 55 60
 Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu
 65 70 75 80
 Val Thr Ala Leu Leu Gly Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu
 85 90 95
 Val Glu Asn Gln Ala Asn Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr
 100 105 110
 Arg Arg Val Asp Asp Ala Thr Val Ala Ile Arg Ser Ala Ile Asn Asn
 115 120 125
 Leu Ile Val Glu Leu Ile Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser
 130 135 140
 Phe Glu Ser Ser Ser Gly Leu Val Trp Thr Ser Gly Pro Ala Thr Tyr
 145 150 155 160
 Gln Leu Gln Gly Pro Gly Ala Pro Gln Gly Pro Gly Ala Pro
 165 170

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 480 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: pBGC261 Non-fusion

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..480

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATG TCT TAC AGT ATC ACT ACT CCA TCT CAG TTC GTG TTC TTG TCA TCA	48
Met Ser Tyr-Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
GCG TGG GCC GAC CCA ATA GAG TTA ATT AAT TTA TGT ACT AAT GCC TTA	96
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
GGA AAT CAG TTT CAA ACA CAA CAA GCT CGA ACT GTC GTT CAA AGA CAA	144
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
TTC AGT GAG GTG TGG AAA CCT TCA CCA CAA GTA ACT GTT AGG TTC CCT	192
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
GAC AGT GAC TTT AAG GTG TAC AGG TAC AAT GCG GTA TTA GAC CCG CTA	240
Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu	

Phe Glu Ser Ser Ser Gly Leu Val Trp Thr Ser Gly Pro Ala Thr
 145 150 155

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Ser Tyr Val Pro Ser Ala Glu Gln Ile Leu Glu Phe Val Lys Gln Ile
 1 5 10 15
 Ser Ser Gln

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 537 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: pBGC289 Leaky Stop

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..537

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATG TCT TAC AGT ATC ACT ACT CCA TCT CAG TTC GTG TTC TTG TCA TCA	48
Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
GCG TGG GCC GAC CCA ATA GAG TTA ATT AAT TTA TGT ACT AAT GCC TTA	96
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
GGA AAT CAG TTT CAA ACA CAA CAA GCT CGA ACT GTC GTT CAA AGA CAA	144
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
TTC AGT GAG GTG TGG AAA CCT TCA CCA CAA GTA ACT GTT AGG TTC CCT	192
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
GAC AGT GAC TTT AAG GTG TAC AGG TAC AAT GCG GTA TTA GAC CCG CTA	240
Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu	
65 70 75 80	

GTC ACA GCA CTG TTA GGT GCA TTC GAC ACT AGA AAT AGA ATA ATA GAA	288
Val Thr Ala Leu Leu Gly Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu	
85 90 95	
GTT GAA AAT CAG GCG AAC CCC ACG ACT GCC GAA ACG TTA GAT GCT ACT	336
Val Glu Asn Gln Ala Asn Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr	
100 105 110	
CGT AGA GTA GAC GAC GCA ACG GTG GCC ATA AGG AGC GCG ATA AAT AAT	384
Arg Arg Val Asp Asp Ala Thr Val Ala Ile Arg Ser Ala Ile Asn Asn	
115 120 125	
TTA ATA GTA GAA TTG ATC AGA GGA ACC GGA TCT TAT AAT CGG AGC TCT	432
Leu Ile Val Glu Leu Ile Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser	
130 135 140	
TTC GAG AGC TCT TCT GGT TTG GTT TGG ACG TCA TAG CAA TTA ACG TCA	480
Phe Glu Ser Ser Ser Gly Leu Val Trp Thr Ser Tyr Gln Leu Thr Ser	
145 150 155 160	
TAT GTT CCA TCT GCA GAG CAG ATC TTG GAA TTC GTT AAG CAA ATC TCG	528
Tyr Val Pro Ser Ala Glu Gln Ile Leu Glu Phe Val Lys Gln Ile Ser	
165 170 175	
AGT CAG TAG	537
Ser Gln	

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 178 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: pBGC289 Leaky Stop
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu	
65 70 75 80	
Val Thr Ala Leu Leu Gly Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu	
85 90 95	
Val Glu Asn Gln Ala Asn Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr	
100 105 110	

Arg Arg Val Asp Asp Ala Thr Val Ala Ile Arg Ser Ala Ile Asn Asn
115 120 125
Leu Ile Val Glu Leu Ile Arg Gly Thr Gly Ser Tyr Asn Arg Ser Ser
130 135 140
Phe Glu Ser Ser Ser Gly Leu Val Trp Thr Ser Tyr Gln Leu Thr Ser
145 150 155 160
Tyr Val Pro Ser Ala Glu Gln Ile Leu Glu Phe Val Lys Gln Ile Ser
165 170 175
Ser Gln

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 468 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: pBGC289 Non-fusion

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..468

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ATG TCT TAC AGT ATC ACT ACT CCA TCT CAG TTC GTG TTC TTG TCA TCA	48
Met Ser Tyr Ser Ile Thr Thr Pro Ser Gln Phe Val Phe Leu Ser Ser	
1 5 10 15	
GCG TGG GCC GAC CCA ATA GAG TTA ATT AAT TTA TGT ACT AAT GCC TTA	96
Ala Trp Ala Asp Pro Ile Glu Leu Ile Asn Leu Cys Thr Asn Ala Leu	
20 25 30	
GGA AAT CAG TTT CAA ACA CAA CAA GCT CGA ACT GTC GTT CAA AGA CAA	144
Gly Asn Gln Phe Gln Thr Gln Gln Ala Arg Thr Val Val Gln Arg Gln	
35 40 45	
TTC AGT GAG GTG TGG AAA CCT TCA CCA CAA GTA ACT GTT AGG TTC CCT	192
Phe Ser Glu Val Trp Lys Pro Ser Pro Gln Val Thr Val Arg Phe Pro	
50 55 60	
GAC AGT GAC TTT AAG GTG TAC AGG TAC AAT GCG GTA TTA GAC CCG CTA	240
Asp Ser Asp Phe Lys Val Tyr Arg Tyr Asn Ala Val Leu Asp Pro Leu	
65 70 75 80	
GTC ACA GCA CTG TTA GGT GCA TTC GAC ACT AGA AAT AGA ATA ATA GAA	288
Val Thr Ala Leu Leu Gly Ala Phe Asp Thr Arg Asn Arg Ile Ile Glu	
85 90 95	
GTT GAA AAT CAG GCG AAC CCC ACG ACT GCC GAA ACG TTA GAT GCT ACT	336
Val Glu Asn Gln Ala Asn Pro Thr Thr Ala Glu Thr Leu Asp Ala Thr	
100 105 110	

CLAIMS

What is claimed is:

1. A polynulceotide encoding fusion protein, the fusion
5 protein consisting essentially of a tobamovirus coat protein
fused to a protein of interest at a fusion joint.
2. A polynucleotide according to Claim 1, wherein the
fusion is an amino terminus fusion.
- 10 3. A polynucleotide according to Claim 1, wherein the
fusion is a carboxy terminus fusion.
4. A polynucleotide according to Claim 1, wherein the
15 fusion is an internal fusion.
5. A polynucleotide according to Claim 1, wherein the
fusion joint comprises a leaky stop codon.
- 20 6. A polynucleotide according to Claim 1, wherein the
fusion joint comprises a leaky start codon.
7. A polynucleotide according to Claim 1, wherein the
protein of interest is an antigen.
- 25 8. A polynucleotide according to claim 1, wherein the
coat protein is a tobacco mosaic virus coat protein.
9. A recombinant plant viral genome comprising a
30 polynucleotide according to Claim 1.
10. A recombinant plant virus particle, comprising a
genome according to claim 9.
- 35 11. A polypeptide encoded by a polynucleotide according
to Claim 1.

12. A recombinant plant virus, wherein the coat protein is encoded by a polynucleotide according to claim 1.

13. A plant cell comprising a polynucleotide according to Claim 9.

10

15

20

25

30

35

PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSIONS

ABSTRACT

The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have many uses. Such uses include use as antigens for inducing the production of antibodies having desired binding properties, e.g., protective antibodies, or for use as vaccine antigens for the induction of protective immunity, including immunity against parasitic infections.

15

20

25

30

35

09057016-040798




FIGURE 1

Plasmid Map of the TMV Transcription Vector pSNC004




FIGURE 2


Diagram of Plasmid Constructions

A) Construction of pBGC291

B) Construction of pBGC261

C) Construction of pBGC289

FIGURE 3






FIGURE 3B

356011



Monoclonal Antibody (NVS3) Binding to TMV291

ELISA OF NVS3 AGAINST TMV291.1B2 AND (AGDR)6




FIGURE 4

ELISA OF NYS1 MAB AGAINST TMV261.1B1 AND (QGPGAP)2 PEPTIDE




FIGURE 5

Express Mail No. EM555262225US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Turpen *et al.*

Group Art Unit: not yet assigned

Serial No.: not yet assigned

Examiner: not yet assigned

Filed: April 7, 1998

Attorney Docket No.:
00801.087.US01

For: **PRODUCTION OF PEPTIDES
IN PLANTS AS VIRAL COAT
PROTEIN FUSIONS**

**PRELIMINARY AMENDMENT
UNDER 37 C.F.R. § 1.607 COPYING CLAIMS
FROM PATENT FOR PURPOSES OF INTERFERENCE**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants present the following claims and request that an interference be declared between these claims and the claims of U.S. Patent No. 5,618,699.

AMENDMENT

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 1, line 14, after "The present application is", please insert --a continuation of application 08/324,003, filed October 14, 1994, which is--.

On page 1, line 17, after "December 30, 1992." please insert:

--The present application is a continuation-in-part of Application No. 08/184,237, filed January 19, 1994, which is a continuation-in-part of Application No. 07/997,733, filed December 30, 1992, now abandoned, which is a continuation of Application No. 07/923,692, filed July 31, 1992, now Patent No. 5,316,931, which is a continuation-in-part of Applications No. 07/600,244, filed October 22, 1990, now abandoned, No. 07/641,617, filed January 16, 1991, now abandoned, Application No. 07/737,899, filed July 26, 1991, now abandoned, and Application No. 07/739,143, filed August 1, 1991, now abandoned. Application No. 07/600,244 is a continuation of Application No. 07/310,881, filed February

17, 1989, now abandoned, which is a continuation-in-part of Applications No. 07/160,766 and No. 07/160,771, both filed on February 26, 1988 and now abandoned. Application No. 07/641,617 is a continuation of Application No. 07/347,637, filed May 5, 1989, now abandoned. Application No. 07/737,899 is a continuation of Application No. 07/363,138, filed June 8, 1989, now abandoned, which is a continuation-in-part of Application No. 07/219,279, filed July 15, 1988, now abandoned. Application No. 07/739,143 is a continuation-in-part of Applications No. 07/600,244, filed October 22, 1990, now abandoned, No. 07/641,617, filed January 16, 1991, now abandoned, and No. 07/737,899, filed July 26, 1991, now abandoned. Benefit is claimed under 35 U.S.C. § 120 with respect to Applications No. 07/923,692, filed July 31, 1992, No. 07/739,143 filed August 1, 1991, No. 07/310,881, filed February 17, 1989, and No. 07/160,766, filed February 26, 1988.--

On page 3, line 10, please replace "plan" with --plant--.

On page 7, line 9, please replace "o" with --of--.

On page 8, line 4, please replace "fusion s" with --fusions--.

On page 10, line 35, please replace "disassembled" with --disassembled--.

On page 11, line 5, please replace "infections" with --infectious--.

On page 11, line 8, please replace "having" with --have--.

On page 11, line 13, please insert --have-- after "may".

IN THE CLAIMS:

Please cancel claims 1-13.

Please add the following claims:

--14. A plant virus vector comprising a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in a plant, the coat protein and a fusion protein of the coat protein and the foreign protein are systemically produced in the plant.--

--15. A process for systemically expressing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

- (a) inoculating a plant with a plant virus vector, wherein the plant virus vector comprises a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in the plant, the coat protein and the fusion protein are systemically produced in the plant; and
- (b) expressing the fusion protein systemically in the plant. --

--16. A process for producing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

- (1) inoculating a plant with a plant virus vector, wherein the plant virus vector comprises a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in a plant, the coat protein and the fusion protein of the coat protein and the foreign protein are systemically produced in the plant;
- (2) recovering virions from the plant; and
- (3) isolating the fusion protein from the virions. --

--17. A virion particle comprising a coat protein of a Tobamovirus and a fusion protein of the coat protein and a foreign protein.--

REMARKS

On April 8, 1997, U.S. Patent No. 5,618,699 (hereinafter, the “699 Patent”) issued to Hiroshi Hamamoto, Yoshinori Sugiyama, Noriaki Nakagawa, Eiji Hashida, Suguru Tsuchimoto, Noriyuki Nakanishi, Yuji Matsunaga and Yoshimi Okada. The patent is entitled PLANT VIRUS VECTOR, PLASMID, PROCESS FOR EXPRESSION OF FOREIGN GENE AND PROCESS FOR OBTAINING FOREIGN GENE PRODUCT and claims a plant virus vector capable of systemically expressing a coat protein fusion protein in a plant. In addition, the patent claims a process for systemically expressing a fusion protein in a plant using the virus vector, a process for producing a fusion protein in a plant using the virus vector, and a virion particle comprising a coat protein of a Tobamovirus and a fusion protein. A copy of this patent is attached as Exhibit A for the Examiner’s convenience.

Claims 14-17 have been added to the subject application. These claims define the same patentable invention as the claims of U.S. Patent No. 5,618,699.

Applicants’ claims are supported in a number of different passages in the subject application. Only representative passages are cited below. Additional passages could have been listed, but have not been included for the sake of brevity.

PATENT CLAIM 1 AND APPLICANT’S CLAIM 14

Patent claim 1 is directed to a plant virus vector capable of expressing a foreign protein in a plant. The foreign protein is expressed as a fusion protein with the coat protein of the virus.

Applicants’ claim 14 corresponds to patent claim 1 and is copied verbatim from the patent. Claim 14 is supported in Applicants’ specification as follows:

Patent Claim 1

1. A plant virus vector comprising

Applicants’ Disclosure

The present invention relates to the field of genetically engineered peptide

production in plants, more specifically, the invention relates to the use of tobamovirus vectors to express fusion proteins.

(Page 1, lines 8-11)

The subject invention provides novel recombinant plant viruses that code for the expression of fusion proteins that consist of a fusion between a plant viral coat protein and a protein of interest.

(Page 4, lines 34-37)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.

(Page 5, lines 14-17)

The TMVCP fusion vectors described in the following examples are based on the U1 or wild type TMV strain and are therefore compared to the parental virus as a control.

(Page 14, lines 8-10)

a viral assembly origin

Detailed information on how to make and use recombinant RNA plant viruses can be found, among other places in U.S. patent 5,316,931 (Donson *et al.*), which is herein incorporated by reference. (Page 10, lines 14-17; Column 10, lines 1-11 of U.S. Patent No. 5,316,931 states: "Initiation of TMV assembly occurs by interreaction between ring-shaped aggregates ("discs") of coat protein (each disc consisting of two layers of 17 subunits) and a unique internal nucleation site in the RNA; a hairpin region about 900 nucleotides from the 3' end in the common strain of TMV. Any RNA, including subgenomic RNAs containing this site, may be packaged into virions. The discs apparently assume a helical form on interaction with the RNA, and assembly (elongation) then proceeds in both directions (but much more rapidly in the 3'- to 5'-direction from the nucleation site).

The expression of the subject coat fusion proteins may be driven by any of a variety of promoters functional in the genome of the recombinant plant viral vector. In a preferred embodiment of the invention, the subject fusion protein are expressed from plant viral subgenomic promoters using vectors as described in U.S. Patent 5,316,931.
(Page 9, lines 27-32)

As tobamovirus coat proteins may self-assemble into virus particles, the virus particles of the invention may be assembled either in vivo or in vitro.
(Page 10, lines 32-34)

and a foreign protein gene

The protein of interest portion of the fusion protein for expression may consist of a peptide of virtually any amino acid sequence...
(Page 5, lines 17-19)

The protein of interest portion of the subject fusion proteins may vary in size from one amino acid residue to over several hundred amino acid residues...
(Page 6, lines 3-5)

linked downstream of a coat protein gene of a Tobamovirus

The fusion proteins of the invention comprise two portions: (i) a plant viral coat protein and (ii) a protein of interest.
(Page 5, lines 5-7)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.
(Page 5, lines 14-17)

The fusion joint may be located at the amino terminus of the coat protein portion of the fusion protein (joined to the carboxyl terminus of the protein of interest).
(Page 6, lines 35-37)

via a nucleotide sequence of a Tobamovirus

Polynucleotide sequences encoding the

which causes readthrough,

subject fusion proteins may comprise a “leaky” stop codon at a fusion joint. The stop codon may be present as the codon immediately adjacent to the fusion joint, or may be located close (e.g., within 9 bases) to the fusion joint. A leaky stop codon may be included in polynucleotides encoding the subject coat fusion protein so as to maintain a desired ratio of fusion protein to wild type coat protein. A “leaky” stop codon does not always result in translational termination and is periodically translated. (Page 8, lines 13-22)

such that upon expression of the vector in a plant, the coat protein and a fusion protein of the coat protein and the foreign protein are systemically produced in the plant.

Thus, by including a leaky stop codon at a fusion joint coding region in a recombinant viral vector encoding a coat fusion protein, the vector may be used to produce both a fusion protein and a second smaller protein, e.g., the viral coat protein. (Page 8, lines 33-37)

In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied. (Page 10, lines 28-32)

PATENT CLAIM 9 AND APPLICANTS’ CLAIM 15

Patent claim 9 is directed to a process for systemically expressing a fusion protein of a coat protein and a foreign protein in a plant.

Applicants’ new claim 15 corresponds to patent claim 9 and is copied verbatim from the ‘699 patent. Claim 15 is supported in Applicants’ specification as follows:

Patent Claim 9

9. A process for systemically expressing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

(a) inoculating a plant with a plant virus vector,

Applicants’ Disclosure

The recombinant plant viruses of the invention provide for systemic expression of the fusion protein, by systemically infecting cells in a plant. (Page 4, line 37 to page 5, line 2)

The invention also provides for recombinant plant cells comprising the

subject coat fusion proteins and/or virus particles comprising the subject coat fusion proteins. These plant cells may be produced either by infecting plant cells (either in culture or in whole plants) with infectious virus particles of the invention or with polynucleotides encoding the genomes of the infectious virus particles of the invention.

(Page 11, lines 1-7)

wherein the plant virus vector comprises

The present invention relates to the field of genetically engineered peptide production in plants, more specifically, the invention relates to the use of tobamovirus vectors to express fusion proteins.

(Page 1, lines 8-11)

The subject invention provides novel recombinant plant viruses that code for the expression of fusion proteins that consist of a fusion between a plant viral coat protein and a protein of interest.

(Page 4, lines 34-37)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.

(Page 5, lines 14-17)

The TMVCP fusion vectors described in the following examples are based on the U1 or wild type TMV strain and are therefore compared to the parental virus as a control.

(Page 14, lines 8-10)

a viral assembly origin

Detailed information on how to make and use recombinant RNA plant viruses can be found, among other places in U.S. patent 5,316,931 (Donson *et al.*), which is herein incorporated by reference.

(Page 10, lines 14-17; Column 10, lines 1-11 of U.S. Patent No. 5,316,931 states: "Initiation of TMV assembly occurs by interreaction between ring-shaped aggregates ("discs") of coat protein (each

disc consisting of two layers of 17 subunits) and a unique internal nucleation site in the RNA; a hairpin region about 900 nucleotides from the 3' end in the common strain of TMV. Any RNA, including subgenomic RNAs containing this site, may be packaged into virions. The discs apparently assume a helical form on interaction with the RNA, and assembly (elongation) then proceeds in both directions (but much more rapidly in the 3'- to 5'-direction from the nucleation site).

The expression of the subject coat fusion proteins may be driven by any of a variety of promoters functional in the genome of the recombinant plant viral vector. In a preferred embodiment of the invention, the subject fusion protein are expressed from plant viral subgenomic promoters using vectors as described in U.S. Patent 5,316,931.
(Page 9, lines 27-32)

As tobamovirus coat proteins may self-assemble into virus particles, the virus particles of the invention may be assembled either in vivo or in vitro.
(Page 10, lines 32-34)

The protein of interest portion of the fusion protein for expression may consist of a peptide of virtually any amino acid sequence...
(Page 5, lines 17-19)

The protein of interest portion of the subject fusion proteins may vary in size from one amino acid residue to over several hundred amino acid residues...
(Page 6, lines 3-5)

The fusion proteins of the invention comprise two portions: (i) a plant viral coat protein and (ii) a protein of interest.
(Page 5, lines 5-7)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of

and a foreign protein gene

linked downstream of a coat protein gene of a Tobamovirus

tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.

(Page 5, lines 14-17)

The fusion joint may be located at the amino terminus of the coat protein portion of the fusion protein (joined to the carboxyl terminus of the protein of interest).

(Page 6, lines 35-37)

via a nucleotide sequence of a Tobamovirus which causes readthrough,

Polynucleotide sequences encoding the subject fusion proteins may comprise a "leaky" stop codon at a fusion joint. The stop codon may be present as the codon immediately adjacent to the fusion joint, or may be located close (e.g., within 9 bases) to the fusion joint. A leaky stop codon may be included in polynucleotides encoding the subject coat fusion protein so as to maintain a desired ratio of fusion protein to wild type coat protein. A "leaky" stop codon does not always result in translational termination and is periodically translated.

(Page 8, lines 13-22)

such that upon expression of the vector in a plant, the coat protein and the fusion protein are systemically produced in the plant; and

Thus, by including a leaky stop codon at a fusion joint coding region in a recombinant viral vector encoding a coat fusion protein, the vector may be used to produce both a fusion protein and a second smaller protein, e.g., the viral coat protein.

(Page 8, lines 33-37)

In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied.

(Page 10, lines 28-32)

(b) expressing the fusion protein systemically in the plant.

The recombinant plant viruses of the invention provide for systemic expression of the fusion protein, by systemically infecting cells in a plant. (Page 4, line 37 to page 5, line 2)

PATENT CLAIM 13 AND APPLICANTS' CLAIM 16

Patent claim 13 is directed to a process for producing a fusion protein of a coat protein and a foreign protein in a plant.

Applicants' new claim 16 corresponds to patent claim 13 and is copied verbatim from the patent. Claim 13 is supported in Applicants' specification as follows.

Patent Claim 13

13. A process for producing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

(1) inoculating a plant with a plant virus vector,

wherein the plant virus vector comprises

Applicants' Disclosure

Thus by employing the recombinant plant viruses of the invention, large quantities of a protein of interest may be produced. (Page 5, lines 2-4)

The invention also provides for recombinant plant cells comprising the subject coat fusion proteins and/or virus particles comprising the subject coat fusion proteins. These plant cells may be produced either by infecting plant cells (either in culture or in whole plants) with infectious virus particles of the invention or with polynucleotides encoding the genomes of the infectious virus particles of the invention. (Page 11, lines 1-7)

The present invention relates to the field of genetically engineered peptide production in plants, more specifically, the invention relates to the use of tobamovirus vectors to express fusion proteins. (Page 1, lines 8-11)

The subject invention provides novel recombinant plant viruses that code for the expression of fusion proteins that

consist of a fusion between a plant viral coat protein and a protein of interest.
(Page 4, lines 34-37)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.
(Page 5, lines 14-17)

The TMVCP fusion vectors described in the following examples are based on the U1 or wild type TMV strain and are therefore compared to the parental virus as a control.
(Page 14, lines 8-10)

a viral assembly origin

Detailed information on how to make and use recombinant RNA plant viruses can be found, among other places in U.S. patent 5,316,931 (Donson *et al.*), which is herein incorporated by reference.
(Page 10, lines 14-17; Column 10, lines 1-11 of U.S. Patent No. 5,316,931 states: "Initiation of TMV assembly occurs by intereaction between ring-shaped aggregates ("discs") of coat protein (each disc consisting of two layers of 17 subunits) and a unique internal nucleation site in the RNA; a hairpin region about 900 nucleotides from the 3' end in the common strain of TMV. Any RNA, including subgenomic RNAs containing this site, may be packaged into virions. The discs apparently assume a helical form on interaction with the RNA, and assembly (elongation) then proceeds in both directions (but much more rapidly in the 3'- to 5'-direction from the nucleation site)."

The expression of the subject coat fusion proteins may be driven by any of a variety of promoters functional in the genome of the recombinant plant viral vector. In a preferred embodiment of the invention, the subject fusion protein are expressed from plant viral subgenomic

promoters using vectors as described in U.S. Patent 5,316,931.
(Page 9, lines 27-32)

As tobamovirus coat proteins may self-assemble into virus particles, the virus particles of the invention may be assembled either in vivo or in vitro.
(Page 10, lines 32-34)

and a foreign protein gene

The protein of interest portion of the fusion protein for expression may consist of a peptide of virtually any amino acid sequence...
(Page 5, lines 17-19)

The protein of interest portion of the subject fusion proteins may vary in size from one amino acid residue to over several hundred amino acid residues...
(Page 6, lines 3-5)

linked downstream of a coat protein gene of a Tobamovirus

The fusion proteins of the invention comprise two portions: (i) a plant viral coat protein and (ii) a protein of interest.
(Page 5, lines 5-7)

In a preferred embodiment of the invention, the 17.5 Kda coat protein of tobacco mosaic virus is used in conjunction with a tobacco mosaic virus derived vector.
(Page 5, lines 14-17)

The fusion joint may be located at the amino terminus of the coat protein portion of the fusion protein (joined to the carboxyl terminus of the protein of interest). (Page 6, lines 35-37)

via a nucleotide sequence of a Tobamovirus which causes readthrough,

Polynucleotide sequences encoding the subject fusion proteins may comprise a "leaky" stop codon at a fusion joint. The stop codon may be present as the codon immediately adjacent to the fusion joint, or may be located close (e.g., within 9 bases) to the fusion joint. A leaky stop codon may be included in polynucleotides encoding the subject coat fusion protein so as to maintain a

09057015-040798

such that upon expression of the vector in a plant, the coat protein and the fusion protein are systemically produced in the plant;

desired ratio of fusion protein to wild type coat protein. A "leaky" stop codon does not always result in translational termination and is periodically translated. (Page 8, lines 13-22)

Thus, by including a leaky stop codon at a fusion joint coding region in a recombinant viral vector encoding a coat fusion protein, the vector may be used to produce both a fusion protein and a second smaller protein, e.g., the viral coat protein. (Page 8, lines 33-37)

In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied. (Page 10, lines 28-32)

the coat protein and the fusion protein of the coat protein and the foreign protein are systemically produced in the plant;

The recombinant plant viruses of the invention provide for systemic expression of the fusion protein, by systemically infecting cells in a plant. (Page 4, line 37 to page 5, line 2)

Thus by including a leaky stop codon at a fusion joint coding region in a recombinant viral vector encoding a coat fusion protein, the vector may be used to produce both a fusion protein and a second smaller protein, e.g., the viral coat protein. (Page 8, lines 33-37)

In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied. (Page 10, lines 28-32)

(2) recovering virions from the plant; and

In addition to providing the described viral coat fusion proteins, the invention also provides for virus particles that comprise the subject fusion proteins.

09057015-040798

(Page 10, lines 24-26)

(3) isolating the fusion protein from the virions.

The virus particles may also be conveniently disassembled using well known techniques so as to simplify the purification of the subject fusion proteins, or portions thereof.
(Page 10, lines 34-37)

In another embodiment of the invention, the fusion joints on the subject coat fusion proteins are designed so as to comprise an amino acid sequence that is a substrate for protease. By providing a coat fusion protein having such a fusion joint, the protein of interest may be conveniently derived from the coat protein fusion by using a suitable proteolytic enzyme.
(Page 9, lines 19-25)

PATENT CLAIM 16 AND APPLICANTS' CLAIM 17

Patent claim 16 is directed to a virion particle comprising a coat protein of a Tobamovirus and a fusion protein of the coat protein and a foreign protein.

Applicants' claim 17 corresponds to patent claim 16 and is copied verbatim from the patent. Claim 17 is supported in Applicants' specification as follows:

Patent Claim 16

16. A virion particle comprising a coat protein of a Tobamovirus and a fusion protein of the coat protein and a foreign protein.

Applicants' Disclosure

In addition to providing the described viral coat fusion proteins, the invention Also provides for virus particles that comprise the subject fusion proteins. The coat of the virus particles of the invention may consist entirely of coat fusion protein. In another embodiment of the virus particles of the invention, the virus particle coat may consist of a mixture of coat fusion proteins and non-fusion coat protein, wherein the ratio of the two proteins may be varied.
(Page 10, lines 24-32)

PROPOSED COUNTS

The following four counts are proposed for purposes of interference:

PROPOSED COUNT 1

1. A plant virus vector comprising a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in a plant, the coat protein and a fusion protein of the coat protein and the foreign protein are systemically produced in the plant.

Proposed Count 1 corresponds exactly to patent claim 1. Claims 2-7 and claims 14-15 are dependent upon claim 1. Thus, claim 1 encompasses all of the subject matter of claims 2-7 and 14-15.

PROPOSED COUNT 2

2. A process for systemically expressing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

- (a) inoculating a plant with a plant virus vector, wherein the plant virus vector comprises a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in the plant, the coat protein and the fusion protein are systemically produced in the plant; and
- (b) expressing the fusion protein systemically in the plant.

Proposed Count 2 corresponds exactly to patent claim 9. Claims 10-12 are dependent upon claim 9. Thus, claim 9 encompasses all of the subject matter of claims 10-12.

PROPOSED COUNT 3

3. A process for producing a fusion protein of a coat protein and a foreign protein in a plant comprising the steps of:

- (1) inoculating a plant with a plant virus vector, wherein the plant virus vector comprises a viral assembly origin and a foreign protein gene linked downstream of a coat protein gene of a Tobamovirus via a nucleotide sequence of a Tobamovirus which causes readthrough, such that upon expression of the vector in a plant, the coat protein and the fusion protein of the coat protein and the foreign protein are systemically produced in the plant;
- (2) recovering virions from the plant; and
- (3) isolating the fusion protein from the virions.

Proposed Count 3 corresponds exactly to patent claim 13.

PROPOSED COUNT 4

4. A virion particle comprising a coat protein of a Tobamovirus and a fusion protein of the coat protein and a foreign protein.

Proposed Count 4 corresponds exactly to patent claim 16.

The Remaining Independent Claims

The remaining independent claims in the '699 Patent are claims 17, 18, 22 and 24. Patent claim 17 is not patentably distinct from patent claim 9 (Proposed Count 2), as the former merely recites the subspecies coat protein of a Tobamovirus, which is encompassed by claim 9.

Patent claim 18 is not patentable over the corresponding generic patent claim 1 (Proposed Count 1), as claim 18 merely recites the subspecies tobacco mosaic viral (TMV) vector and specific DNA readthrough sequences, which are encompassed by claim 1. Claims 19-21 depend from claim 18.

Patent claim 22 is not patentable over the corresponding generic patent claim 9 (Proposed Count 2), as claim 22 merely recites the subspecies TMV vector and TMV coat protein, which are encompassed by claim 9. Claim 23 depends from claim 22.

Patent claim 24 is not patentable over the corresponding generic patent claim 13 (Proposed Count 3), as claim 24 merely recites the subspecies TMV vector and TMV coat protein, which are encompassed by claim 13. Claim 25 depends from claim 24.

CLAIMS TO BE DESIGNATED AS CORRESPONDING TO THE COUNTS

As noted in 37 C.F.R. § 1.606, all claims that “define the same patentable invention as the count shall be designated as corresponding to the count” and “any single patent claim will be presumed...not to contain separate patentable inventions.”

PROPOSED COUNT 1

Claims 2-8 and 14-15 depend from claim 1 in U.S. Patent No. 5,618,699.

Additionally, as explained above, claim 18 is not patentable over the corresponding generic claim 1 as it merely recites a subspecies of claim 1. Claims 19-21 depend from claim 18. Thus, applying the provisions of 37 C.F.R. § 1.606 to these claims, claims 1-8, 14-15 and 18-21 in the ‘699 patent are directed to the same patentable invention. Accordingly, claims 1-8, 14-15 and 18 should be designated as corresponding to Proposed Count 1.

Applicants’ new claim 14 should also be designated as corresponding to Proposed Count 1, as this claim defines the same patentable invention as patent claims 1-8, 14-15 and 18-21.

PROPOSED COUNT 2

Applicants' Proposed Count 2 is identical to claim 9 in U.S. Patent No. 5,618,699. Claims 10-12 depend from claim 9. Additionally, as explained above, claim 17 and claim 22 in the patent are not patentable over the corresponding generic claim 9, as each merely recites a subspecies coat protein and/or viral vector of claim 9. Claim 23 depends from claim 22. Thus, applying the provisions of 37 C.F.R. § 1.606 to these claims, claims 9-12, 17 and 22 are directed to the same patentable invention. Accordingly, claims 9-12, 17, 22 and 23 should be designated as corresponding to Proposed Count 2.

Applicants' new claim 15 should also be designated as corresponding to Proposed Count 2, as this claim defines the same patentable invention as patent claims 9-12, 17, 22 and 23.

PROPOSED COUNT 3

Applicants' Proposed Count 3 is identical to claim 13 in U.S. Patent No. 5,618,699. No other claims depend from claim 13. However, as explained above, claim 24 is not patentable over the corresponding generic claim 13 as it merely recites a subspecies TMV vector and coat protein of claim 13. Claim 25 depends from claim 24. Thus, applying the provisions of 37 C.F.R. § 1.606 to these claims, claims 13, 24 and 25 are directed to the same patentable invention. Accordingly, claims 13, 24 and 25 should be designated as corresponding to Proposed Count 3.

Applicants' new claim 16 should also be designated as corresponding to Proposed Count 3, as this claim defines the same patentable invention as patent claims 13, 24 and 25.

PROPOSED COUNT 4

Applicants' Proposed Count 4 corresponds to claim 16 of the '699 Patent. No other claims depend from claim 16. Accordingly, claim 16 of the '699 Patent should be designated as corresponding to Proposed Count 4.

Applicants' new claim 17 should also be designated as corresponding to Proposed Count 4, as this claim defines the same patentable invention as patent claim 16.

The designation of Applicants' claims 14-17 as corresponding to Proposed Counts 1-4, respectively, is not to be construed as Applicants' acquiescence in the correctness of the designation or the correctness of the Counts or a concession that each claim is directed to a single patentable invention. Applicants reserve the right to challenge to propriety of the Proposed Counts, the designation of any claim as corresponding to a particular Proposed Count, and the patentability of any claim during the preliminary motion period in an interference, or otherwise.

**ENTITLEMENT TO EARLIER
FILING DATE UNDER 35 U.S.C. § 120**

Applicants have amended the specification to claim the benefit of earlier-filed related applications. An identical amendment was made to the parent U.S. Patent Application Serial No. 08/324,003, and was entered by the Examiner as indicated in the Office Action mailed December 8, 1997.

It should also be noted that in parent application 08/324,003, in the Office Action mailed February 27, 1997, the Examiner stated:

Applicants' effective filing date of **February 1989** has obviated the prior art rejections over Takamatsu *et al.*, WO 92/18618 **and Hamamoto *et al.***
(emphasis added)

The Hamamoto reference cited by the Examiner is Hamamoto, H., Sugiyama, Y., Nakagawa, N., Hashida, E., Matsunaga, Y., Takemoto, S., Watanabe, Y., and Okada, Y. 1993b, "A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato," Bio/Technology 11:930-932 (1993).

COMPLIANCE WITH 37 C.F.R. § 1.607(a)

This request for interference complies with the requirements of 37 C.F.R. § 1.607(a):

- (1) The patent is identified as U.S. Patent No. 5,618,699 to Hamamoto et al.;
- (2) At least one proposed counts have been presented;
- (3) Claims in the '699 Patent corresponding to each Proposed Count:

- (a) Claims 1-8, 14-15 and 18-21 in the '699 Patent should be designated as corresponding to Proposed Count 1;
- (b) Claims 9-12, 17 and 22-23 in the '699 Patent should be designated as corresponding to Proposed Count 2;
- (c) Claims 13, 24 and 25 in the '699 Patent should be designated as corresponding to Proposed Count 3;
- (d) Claim 16 in the '699 Patent should be designated as corresponding to Proposed Count 4;
- (4) Applicants' claims corresponding to each Proposed Count:
 - (a) Applicants' claim 14 should be designated as corresponding to Proposed Count 1;
 - (b) Applicants' claim 15 should be designated as corresponding to Proposed Count 2;
 - (c) Applicants' claim 16 should be designated as corresponding to Proposed Count 3;
 - (d) Applicants' claim 17 should be designated as corresponding to Proposed Count 4;
- (5) Applicants' claims 14-17 have been applied to the subject application.

Applicants respectfully request that an interference be expeditiously declared with U.S. Patent 5,618,699. Applicants further request that they be accorded benefit of the filing date of October 14, 1994.


A showing under 37 C.F.R. § 1.608(b) is not required, because Applicants' effective filing date of October 14, 1994 antedates the date of November 30, 1994, which is the earliest date that could possibly be accorded to Hamamoto et al. Applicant does not concede that Hamamoto et al. are entitled to the filing date of November 30, 1994.

The Commissioner is hereby authorized to charge any fee or underpayment, or credit any overpayment, to the Howrey & Simon Deposit Account No. 08-3038 for any matter in

connection with this communication, including any fee for extension of time which may be required.

Respectfully submitted,

Dated: April 7, 1998


for: Albert P. Halluin Reg. No. 25,227

HOWREY & SIMON
1299 Pennsylvania Avenue, N.W.
Box 34
Washington, D. C. 20004-2402
Tel: (650) 463-8109
Fax: (650) 463-8400

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSIONS

the specification of which:

☐ is attached hereto

☒ was filed in the United States on October 14, 1994 as Application Serial No. 08/324,003
with amendment(s) filed on _____ (if applicable)

(for declaration not accompanying application)

☐ was filed as PCT international application Serial No. _____ on _____ and was amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119/§172 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119/172
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>




I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaianni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Albert P. Halluin (Reg. No. 25227), and Marcia H. Sundeen (Reg. No. 30893), whose address is Pennie & Edmonds, 1155 Avenue of the Americas, New York, New York 10036, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: PENNIE & EDMONDS 1155 AVENUE OF THE AMERICAS NEW YORK, N.Y. 10036-2711				DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS (212) 790-9090	
201	FULL NAME OF INVENTOR	LAST NAME TURPEN	FIRST NAME THOMAS	MIDDLE NAME H.	
	RESIDENCE & CITIZENSHIP	CITY Vacaville	STATE OR FOREIGN COUNTRY California	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 319 Woodcrest Drive	CITY Vacaville	STATE OR COUNTRY California	ZIP CODE 95688
202	FULL NAME OF INVENTOR	LAST NAME REINL	FIRST NAME STEPHEN	MIDDLE NAME J.	
	RESIDENCE & CITIZENSHIP	CITY Sacramento	STATE OR FOREIGN COUNTRY California	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 920 - 9th Avenue	CITY Sacramento	STATE OR COUNTRY CALIFORNIA	ZIP CODE 95818
203	FULL NAME OF INVENTOR	LAST NAME GRILL	FIRST NAME LAURENCE	MIDDLE NAME K.	
	RESIDENCE & CITIZENSHIP	CITY Vacaville	STATE OR FOREIGN COUNTRY California	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 3570 Cantelow Road	CITY Vacaville	STATE OR COUNTRY California	ZIP CODE 95688
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 	SIGNATURE OF INVENTOR 202 	SIGNATURE OF INVENTOR 203 
DATE 12/21/94	DATE 12/21/94	DATE 12/21/94
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: ☒ Application of: Thomas H. Turpen, Stephen J. Reinl, and Lawrence K. Grill

☒ Serial No.: 08/324,003

Group Art Unit: Not Yet Assigned

☒ Filed: October 14, 1994

Examiner: Not Yet Assigned

For: PRODUCTION OF PEPTIDES IN
PLANTS AS VIRAL COAT PROTEIN
FUSIONS

Attorney Docket No.:
8129-087-999

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
[37 CFR 1.9(f) and 1.27(c)] - Small Business Concern

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act in behalf of
the concern identified below:

Name of concern Biosource Technologies, Inc.

Address of concern 3333 Vaca Valley Parkway

Vacaville, CA 95688

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the person employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern and/or there is an obligation under contract or law by the inventor(s) to convey rights to the small business concern with regard to the invention, entitled "PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSIONS" by inventor(s) Thomas H. Turpen, Stephen J. Reinl, and Laurence K. Grill described in

- ☐ the specification filed herewith
☒ application serial no. 08/324,003 filed October 14, 1994

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention,

or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28 (b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon, or any patent to which this verified statement is directed.

Send correspondence to: PENNIE & EDMONDS Direct Telephone calls to:
1155 Avenue of the Americas PENNIE & EDMONDS
New York, N.Y. 10036-2711 (212) 790-9090

Name of person signing David R. McGee
Title of person other than owner Vice President, Operations
Address of person signing Biosource Technologies, Inc.; 3333 Vaca Valley Parkway;
Vacaville, CA 95688
Signature David R. McGee Date 1/9/95

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)